PMID- 35353920
OWN - NLM
STAT- MEDLINE
DCOM- 20220715
LR  - 20220716
IS  - 1098-2825 (Electronic)
IS  - 0887-8013 (Print)
IS  - 0887-8013 (Linking)
VI  - 36
IP  - 7
DP  - 2022 Jul
TI  - Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly 
      diagnosed multiple myeloma in real-world analysis.
PG  - e24375
LID - 10.1002/jcla.24375 [doi]
LID - e24375
AB  - INTRODUCTION: The gain/amplification (amp) of 1q21 is one of the most common 
      high-risk chromosome abnormality (HRCA) in multiple myeloma (MM). The prognostic 
      value of 1q21+ remains to be controversial on the status of gain or amp and the 
      combination of other HRCAs. METHODS: In this retrospective study, we included 318 
      newly diagnosed MM (NDMM) patients who had fluorescence in situ hybridization 
      (FISH) data and treated with novel agents in our department. RESULTS: Our study 
      noted MM patients with amp 1q21 were more likely accompanied with t(4;14), 
      t(14;16), and t(14;20). Patients with amp 1q21 presented with elder age, advanced 
      Revised International Staging System (R-ISS) stages, anemia, and more plasma 
      cells in bone marrow compared to patients with gain 1q21 alone and no 1q21+. 
      Moreover, amp 1q21 alone correlated with shorter progression-free survival (PFS) 
      (22.8m vs. 40.5m vs. 39.6m) and overall survival (OS) (45.2m vs. NA vs. 83.5m) 
      compared with gain 1q21 alone and no FISH abnormalities. Although the high ratio 
      of proteasome inhibitor and immunomodulatory drugs used in patients with amp 
      1q21, the overall response (ORR) was the lowest compared with no 1q21+ and gain 
      1q21. Multivariate analysis defined amp 1q21 as an independent prognostic marker 
      for NDMM patients, rather than gain 1q21. CONCLUSION: The amp 1q21 predict 
      inferior treatment response and survival, especially coexisted with high-risk IgH 
      translocation.
CI  - (c) 2022 The Authors. Journal of Clinical Laboratory Analysis published by Wiley 
      Periodicals LLC.
FAU - Wang, Yu-Tong
AU  - Wang YT
AD  - Department of Hematology, Beijing Jishuitan Hospital, 4th Clinical Medical 
      College of Peking University, Beijing, China.
FAU - Bao, Li
AU  - Bao L
AUID- ORCID: 0000-0002-6436-1492
AD  - Department of Hematology, Beijing Jishuitan Hospital, 4th Clinical Medical 
      College of Peking University, Beijing, China.
FAU - Chu, Bin
AU  - Chu B
AD  - Department of Hematology, Beijing Jishuitan Hospital, 4th Clinical Medical 
      College of Peking University, Beijing, China.
FAU - Chen, Xiao-Huan
AU  - Chen XH
AD  - Department of Hematology, Beijing Jishuitan Hospital, 4th Clinical Medical 
      College of Peking University, Beijing, China.
FAU - Lu, Min-Qiu
AU  - Lu MQ
AD  - Department of Hematology, Beijing Jishuitan Hospital, 4th Clinical Medical 
      College of Peking University, Beijing, China.
FAU - Shi, Lei
AU  - Shi L
AD  - Department of Hematology, Beijing Jishuitan Hospital, 4th Clinical Medical 
      College of Peking University, Beijing, China.
FAU - Gao, Shan
AU  - Gao S
AD  - Department of Hematology, Beijing Jishuitan Hospital, 4th Clinical Medical 
      College of Peking University, Beijing, China.
FAU - Fang, Li-Juan
AU  - Fang LJ
AD  - Department of Hematology, Beijing Jishuitan Hospital, 4th Clinical Medical 
      College of Peking University, Beijing, China.
FAU - Xiang, Qiu-Qing
AU  - Xiang QQ
AD  - Department of Hematology, Beijing Jishuitan Hospital, 4th Clinical Medical 
      College of Peking University, Beijing, China.
FAU - Ding, Yue-Hua
AU  - Ding YH
AD  - Department of Hematology, Beijing Jishuitan Hospital, 4th Clinical Medical 
      College of Peking University, Beijing, China.
LA  - eng
GR  - 2018000021469G223/Beijing Municipal Excellent Talents Foundation/
GR  - ZR-201909/Beijing JST Research Funding/
GR  - QN-201908/Beijing JST Research Funding/
PT  - Journal Article
DEP - 20220330
PL  - United States
TA  - J Clin Lab Anal
JT  - Journal of clinical laboratory analysis
JID - 8801384
SB  - IM
MH  - Chromosome Aberrations
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - *Multiple Myeloma/drug therapy/genetics
MH  - Prognosis
MH  - Retrospective Studies
PMC - PMC9280004
OTO - NOTNLM
OT  - Amp 1q21
OT  - FISH
OT  - high-risk cytogenetic abnormality
OT  - multiple myeloma
COIS- The authors have no conflict of interest.
EDAT- 2022/03/31 06:00
MHDA- 2022/07/16 06:00
PMCR- 2022/03/30
CRDT- 2022/03/30 17:06
PHST- 2022/02/25 00:00 [revised]
PHST- 2021/11/28 00:00 [received]
PHST- 2022/03/15 00:00 [accepted]
PHST- 2022/03/31 06:00 [pubmed]
PHST- 2022/07/16 06:00 [medline]
PHST- 2022/03/30 17:06 [entrez]
PHST- 2022/03/30 00:00 [pmc-release]
AID - JCLA24375 [pii]
AID - 10.1002/jcla.24375 [doi]
PST - ppublish
SO  - J Clin Lab Anal. 2022 Jul;36(7):e24375. doi: 10.1002/jcla.24375. Epub 2022 Mar 
      30.